Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.

doi:10.1182/blood.2024028107

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.

Blood - 25 Sept 2025

Diamond Benjamin, Baughn Linda, Poorebrahim Mansour, Poos Alexandra M, Lee Holly, Kaddoura Marcella, Wiedmeier-Nutor J Erin, Durante Michael, Otteson Gregory, Jevremovic Dragan, Tang Hongwei, Fröhling Stefan, Baertsch Marc A, Papadimitriou Marios, Ziccheddu Bachisio, Jelinek Tomas, Lemoine Cendrine, Rak Alexey, Green Damian J, Landgren Ola, Neri Paola, Bergsagel Leif, Braggio Esteban, Kumar Shaji, Raab Marc S, Fonseca Rafael, Bahlis Nizar, Weinhold Niels, Maura Francesco

Abstract excerpt

ABSTRACT: Monoclonal antibodies targeting CD38 are a therapeutic mainstay in multiple myeloma (MM). Although they have contributed to improved outcomes, most patients still experience disease relapse, and little is known about tumor-intrinsic mechanisms of resistance to these drugs. Antigen escape has been implicated as a mechanism of tumor-cell evasion in immunotherapy. Yet, it is unknown whether MM cells can...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Alleles

Share to Antibodies, Monoclonal

Share to Antibodies, Monoclonal, Humanized

Share to Drug Resistance, Neoplasm

Share to Membrane Glycoproteins

Share to Multiple Myeloma

Share to Tumor Escape

Source

Open in PubMed Open full text

Identifiers

PMID: 40493883
DOI: 10.1182/blood.2024028107
PMCID: PMC12451653

Genes

CD38

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.PMID 40493883Read ↗

CD38 biallelic loss is a recurrent mechanism of resistance to anti-CD38 antibodies in multiple myelomaSemantic proximity Read ↗

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Acquired CD38 gene deletion as a mechanism of tumor antigen escape in multiple myelomaSemantic proximity Read ↗

Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myelomaSemantic proximity Read ↗

Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myelomaSemantic proximity Read ↗

The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D.Semantic proximity Read ↗

Single- and double-hit events in genes encoding immune targets before and after T cell–engaging antibody therapy in MMSemantic proximity Read ↗

Ablation of CD38 in multiple myeloma cells leads to an aggressive phenotype in a mouse xenograft model.Semantic proximity Read ↗

Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.Semantic proximity Read ↗

Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapiesSemantic proximity Read ↗

Target antigen and plasma cell phenotype are critical factors for sensitivity to response-adapted daratumumab therapy.Semantic proximity Read ↗

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.